A：Recent progress includes a 50% year-over-year growth in subscribers using personalized solutions, which has helped drive nearly 50% year-over-year revenue growth for the past few years.

A：Henson Hirst Health's approach to customer service has evolved from helping people access simple treatments for specific conditions to providing personalized multi-conductor care and now plans to help customers proactively manage their health to prevent conditions from materializing.

A：New partnerships and services include collaborations with Novo Nordisk for FDA-approved injectable and oral treatments, a partnership with various pharmaceuticals for FDA-approved oral testosterone treatments, and a strategic investment in Grail for cancer early detection tests. These aim to redefine access to hormonal care, improve outcomes, and offer advanced diagnostics.

A：Henson Hirst Health's 2030 goals include over $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. The company is progressing towards these goals by materializing opportunities quicker than anticipated, with recent advancements in weight loss support and continued growth in specialty areas.

A：The verticalization of compounding infrastructure is the foundation behind Henson Hirst Health's continued growth. It ensures safety, quality, and affordability while enabling the delivery of high-standard services and accessible care.

A：Henson Hirst Health plans to make its services more accessible and personalized by offering micro-dosing options, a range of innovative offerings, and comprehensive whole body lab testing. This will help customers in their weight loss journey and support proactive health measures.

A：Recent offerings include personalized provider-guided treatment plans for low testosterone and a dedicated menopause offering, designed to address the needs of millions of men and women facing symptoms and limited access to effective care.

A：The new offerings in diagnostics and advanced therapies, such as comprehensive whole body lab testing and longevity specialty, will contribute to Henson Hirst Health's future by providing insights, facilitating action, and improving health outcomes. These initiatives aim to make advanced diagnostics and treatments more accessible to a broader population.

A：The company plans to expand globally, starting with the U.S. and the UK, and now moving to Canada. They believe their model can scale to become a leading consumer health platform in Europe. The acquisition of Zaba Global has provided them with the necessary infrastructure to serve customers across several European countries, including the UK, Germany, France, Ireland, and Spain. The company sees international markets as a long-term growth opportunity, potentially generating over 1 billion in annual revenue.

A：The company is preparing for a launch in Canada, which will notably expand their North American presence. With two-thirds of Canadian adults being overweight or living with obesity, there is a significant opportunity to make high-touch care more accessible. They are in active discussions with leading generic manufacturers to ensure they are ready to deliver access through their platform once certain medications become available in generic form in 2026.

A：The company had a strong third quarter with revenue growing 49% year over year to nearly 600 million, while adjusted EBITDA margins were above 13%. They expect to continue investing in areas that enhance the customer experience and drive long-term financial returns. Planned investments include expanding personalized capabilities within their facilities, enhancing the customer experience across new specialties, and making strategic investments in technology and partnerships. They anticipate these investments will lead to greater free cash flow generation in the future.

A：The company's strong cash flow and balance sheet place it in a unique position to strategically deploy capital to expand both organically and through strategic M&A opportunities. They expect to continue investing across the previously mentioned areas and believe these investments will pay off in the form of reduced costs from greater efficiency and unlocking new growth factors for the company. The company's priority is on long-term free cash flow generation and believes that the investments made today will set the foundation for greater free cash flow in the future.

A：Strategic investments include continuing the verticalization and expansion of personalized capabilities within their facilities, expecting to increase the operational footprint and capabilities. They plan to add new specialties and enhance the customer experience, which includes the recent launch of low testosterone offering and others for para menopause and menopause support. The company will continue strategic investments, partnerships, and collaborations to extend their impact and advance their mission. Further plans include investing in technology capabilities to leverage data for better health outcomes and expanding into new markets like Canada, as well as enhancing capabilities in the UK and exploring opportunities in Brazil, Australia, and other Latin American and Asian markets.

A：Hims and Hers are undergoing significant evolution, with new technology, capabilities, specialties, and geographical coverage. One of the most exciting shifts is the upcoming launch of comprehensive whole body diagnostic testing, which will allow subscribers to proactively manage their health and pursue healthier and longer lives, potentially attracting a broader set of consumers and deepening engagement with current ones.

A：For the fourth quarter, the expected revenue is between 605 to 625 million with a year-over-year growth rate of between 26 and 30%. The anticipated adjusted EBITDA is in the range of 55 to 65 million, reflecting a 10% margin at the midpoint. For the full year, the expected revenue is between 2.335 and 2.355 billion, reflecting a year-over-year increase ranging from 58% to 59%. The expected adjusted EBITDA is in the range of 307 to 317 million, reflecting a 13% margin at the midpoint.

A：The key assumptions behind the fourth quarter financial outlook include the migration fulfillment for weight loss products to 503A facilities leading to between 20 to 25 million of headwinds from shorter shipment cadences. These headwinds are expected to normalize in the second half of 2026 as customer refill cohorts accumulate. The company is investing in expanding its internal 503A fulfillment capacity. Additionally, they expect near-term margin headwinds from lowering price points for GLP-1 products, which will normalize in the second half of next year as they progress with the verticalization of the fulfillment capabilities.

A：The company continues to expect at least 50 million of incremental revenue from ZBA in the second half of the year. They also anticipate the continued moderation in the on-demand and sexual health business, with near-term headwinds beginning to ease in 2026 as daily sexual health subscribers and multi-conductor treatment plans become a larger share of the mix.

A：The ongoing shift towards personalized offerings is a key driver of long-term revenue growth and supporting a target of 85% or higher revenue retention. The company plans to invest in the long-term trajectory of its business, with investments starting in the fourth quarter and continuing through 2026. These investments include scaling new categories, building a presence in new markets, and driving greater value to subscribers through innovative partnerships. While this may result in a temporary pause in year-over-year margin expansion, the company believes these investments will meaningfully extend the reach of their platform around the world and meet or exceed their 2030 targets.

A：The company plans to launch whole body lab testing on the platform very soon before the year-end. Full-stack subscription service that includes at-home testing and additional products and services like peptides and a broader longevity offering will be launched in 2026. The biggest hurdles to this type of rollout include the cost of comprehensive testing and ensuring that these services reach a wider audience. However, the company is optimistic about the potential for these offerings to bring about equalization in health testing and is hopeful that the current administration can help further expand access to certain peptides.

A：The company is confident in reaccelerating core growth as they see the world rapidly evolving with new specialties. As diagnostics capabilities ramp up, they expect a faster pace in providing personalized treatments and expanding into new specialties. Specific growth levers include new specialties, lab diagnostics, and shifting towards proactive consumer care management. In the second half of the year, they expect a shift in the weight loss cadences and the addition of new consumer segments like testosterone in the Hims brand and menopause and longevity in the Hers brand. These strategies are expected to contribute to strong growth drivers in the future.

A：The company's strategy for the JP one solutions on the platform includes maintaining a 'bread and assortment' approach, aiming to provide patients with more personalized options for better outcomes. They are excited about re-engaging with Novo for the moob pill and anticipate future innovation in biotech. The company is pursuing a wide range of treatments and expects to continue scaling, optimizing, and integrating these solutions into the platform to offer value to subscribers.

A：The weight loss specialty contributes to the company's growth through a high touch model that resonates with subscribers, resulting in strong retention across the platform. The strategy includes scaling and optimizing the verticalized model, and lowering price points to make it more accessible to a broader audience, which is showing early promising signs. The company plans to invest in vertically scaling operations to pass these benefits on to subscribers.

A：The hers business has various growth drivers including legacy categories in dermatology that are growing quickly, the robust growth of the oral and personalized weight business, and new categories in hormonal health, perimenopause, longevity diagnostics. These multiple growth engines allow the business to extend to new audiences and therapeutic categories. Key investments include scaling the platform to reach new demographics and therapeutic areas, as well as leveraging diagnostics for proactive care management. The company is also investing in brands and mental health support to capture consumers early in their journeys.

A：While it's too early to provide specific details, the company's past experience with rapid margin expansion after investments and a broader set of levers available suggest confidence in future accretive potential. New capabilities and specialties are expected to contribute to this growth, alongside investments in talent with high ROI potential. The company aims to maintain and possibly improve margins in the mid-term, although a precise forecast for 2026 is not provided.

A：The company has a strong focus on deploying capital wisely, balancing strong free operating cash flow and a solid cash position. They prioritize investments in business growth levers such as extending personalized capabilities, enhancing the platform, and entering international markets. At the same time, they consider actions that align intrinsic and market value, including share buybacks. The company reviews valuation dynamics and acts when there is a meaningful disconnect between market value and intrinsic value.

A：Negotiating with Novo for a partnership related to job performance solutions involves discussing the potential downsides and benefits for both parties. The company is excited about engaging with Novo and is committed to ensuring patients have access to affordable treatments. The goal is to provide the right course of treatment and connect patients with the right providers. While specific conversations remain private, the focus is on ensuring patient options remain optimal and affordable.

A：The continued strength across each component of the weight loss specialty is attributed to robust growth in the oral business, driven by broader eligibility requirements and the ability to reach a wider audience of people apprehensive about injectables. The injectable side also remains strong and is on pace to achieve the 725 million or greater target set earlier in the year.

A：The company is facing a 20 to 25 million headwind, which is primarily due to shipping GLC 1 in smaller shipments and recognizing revenue when shipments occur, not when orders are placed. As consumers renew more frequently due to the smaller shipment cadence, there is a stacking of cohorts that compound each quarter. This dynamic is expected to normalize by the back half of next year as the consumers renew.

A：The company plans for international expansion by investing in a network of creative acquisition, great teams, and operational capabilities. They have learned from experiences in various markets and now aim to bring their winning U.S. model to key international markets. Unique aspects in each country include local dynamics, consumer distinctions, and regulatory differences, but there is a consistent demand for high-touch, consumer-centric care.

A：The company's strategy for whole body lab testing is to offer it at cost-effective rates, as part of a diverse portfolio that also includes diagnostic opportunities leading to advanced treatment care, and bundled services for diagnostics within core treatment pathways. They aim to vertically integrate the infrastructure to optimize lead generation and reduce costs, becoming a trusted partner for personalized care recommendations. This strategy aligns with their goal to be action-oriented and precise in guiding the next steps for patient-centered care.

A：There has been a focus on the levers that deliver strong marketing leverage, including increasing acquisition from organic and lower-cost channels and stronger retention as more users opt for personalized solutions. The company sees a wide array of growth opportunities, such as new specialty launches and expanding into new markets. They intend to continue investing in a manner consistent with their historical capital allocation framework, targeting a payback period of one year. The company expects significant growth in 2026 and plans to invest accordingly, maintaining confidence in their revenue and EBITDA targets of 6.5 billion and 1.3 billion respectively.